Multiscale Modelling to Prevent RNA Aberrant Phase Transitions

IN-PHASE

Duration

5 years

Website

https://cordis.europa.eu/project/id/101160499

Partners

1 partner

Budget

€1,5 million

Description

IN‑PHASE (ERC Starting Grant ID 101160499) addresses how cellular biomolecular condensates—dynamic liquid‑like assemblies of proteins and RNA near the core of many cellular processes—can transition into pathological solid aggregates, often implicated in age‑related and neurodegenerative diseases. The project, led by Dr. Jorge Reñé‑Espinosa (UCM/CSIC), aims to develop a multiscale computational platform by integrating coarse‑grained force fields and atomistic molecular dynamics. This approach will: 1) Decode sequence‑encoded features in RNA/proteins that regulate condensate behavior. 2) Elucidate forces and triggers that push functional condensates toward pathological solid states. 3) Define strategies to prevent deleterious transitions, keeping condensates in their functional phase. By combining physics-based modelling at nested scales, IN‑PHASE will uncover molecular grammars of RNA/protein phase behavior and propose interventions that preserve cellular function.

MATICAL’s role

Proposal review

Programme / Type

Horizon Europe | ERC Starting Grant

Area

Computational biophysics, molecular dynamics, RNA/protein phase separation, neurodegeneration

Ready to elevate your innovation journey?

Let us guide you

The process

Description

MATICAL’s role

Proposal review

Programme / Type

Horizon Europe | ERC Starting Grant

Area

Computational biophysics, molecular dynamics, RNA/protein phase separation, neurodegeneration

Let's innovate with purpose!

We bring structure to complex ideas. With a decade of experience and a track record of success across multiple sectors, we help our partners secure funding, accelerate growth, and deliver results that endure. Whether you’re developing breakthrough technologies or advancing science, we’re here to help you make it happen.

Partners & Collaborative Networks

We support leading international industries, disruptive start-ups, and cutting-edge research organizations in their innovation and R&D, particularly in healthcare, green energy, new materials, environmental sciences, and computing technologies.